Dr Nair introduces a new video series surrounding identification of and key treatment strategies for Alzheimer disease.
Kavita Nair, PhD
Advertisement
Articles by Kavita Nair, PhD
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.
Advertisement
Latest Updated Articles
- Comparative Effectiveness of Early Natalizumab Treatment in JC Virus-Negative Relapsing-Remitting Multiple Sclerosis
Published: April 19th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
5
